Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference

Rhea-AI Summary

Fusion Pharmaceuticals, a clinical-stage oncology firm, will participate in the "Novel Oncology Targets" panel at the Cowen 41st Annual Health Care Conference on March 1, 2021, at 1:20 PM EST. CEO John Valliant will represent the company, showcasing its innovative work in developing next-generation radiopharmaceuticals. Fusion's lead program, FPI-1434, is currently undergoing Phase 1 clinical trials, focusing on targeted therapies for various tumor types using proprietary alpha particle emitting isotopes.

HAMILTON, ON and BOSTON, Feb. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the "Novel Oncology Targets" panel discussion at the Cowen 41^st Annual Health Care Conference on Monday, March 1, 2021 at 1:20pm EST. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform technology.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-cowen-41st-annual-health-care-conference-301233848.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

When is Fusion Pharmaceuticals participating in the Cowen 41st Annual Health Care Conference?

Fusion Pharmaceuticals will participate in the conference on March 1, 2021, at 1:20 PM EST.

Who will represent Fusion Pharmaceuticals at the Cowen conference?

CEO John Valliant will represent Fusion Pharmaceuticals at the Cowen conference.

What is the focus of Fusion Pharmaceuticals' clinical development?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals as precision medicines.

What is Fusion's lead program currently undergoing?

Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

What types of therapies does Fusion Pharmaceuticals develop?

Fusion Pharmaceuticals develops targeted radiopharmaceutical cancer therapies for a broad array of tumor types.